Post-Cardiac Arrest Care — Part 4: Seizure Management, Organ Donation & Long-Term Recovery
Continuous EEG monitoring, seizure and status epilepticus treatment, organ donation considerations, cardiac rehabilitation, ICD evaluation, cognitive recovery, and quality metrics after cardiac arrest.
1. Seizures After Cardiac Arrest — Overview
Seizures and seizure-like phenomena are common in the post-cardiac arrest population, occurring in approximately 10–35% of comatose survivors. The spectrum ranges from isolated electrographic seizures detectable only on continuous electroencephalography (cEEG) to overt convulsive status epilepticus. The clinical significance, prognostic implications, and management of post-arrest seizures depend critically on accurate classification and characterization.1 2 3
1.1 Epidemiology
| Feature | Data |
|---|---|
| Incidence of electrographic seizures | 10–35% of comatose post-arrest patients |
| Incidence of non-convulsive status epilepticus (NCSE) | 10–25% of comatose patients on cEEG |
| Incidence of convulsive status epilepticus (CSE) | 5–10% |
| Timing of onset | Typically within the first 24–72 hours after ROSC; may occur during TTM, rewarming, or after sedation lightening |
| Association with outcome | Post-arrest seizures are associated with poor neurologic outcome, but the association is not absolute — treatment of seizures may improve outcomes in some patients, and seizures on a reactive EEG background carry a better prognosis than seizures on a suppressed background |
1.2 Pathophysiology
Post-anoxic seizures result from:
- Cortical hyperexcitability due to selective neuronal injury, loss of inhibitory interneurons, and disruption of normal GABAergic signaling
- Excitotoxicity from excessive glutamate release during and after global ischemia
- Metabolic derangements (electrolyte abnormalities, glucose fluctuations, acid-base disturbances) that lower the seizure threshold
- Reperfusion injury and oxidative stress
- Cortical laminar necrosis providing a structural substrate for epileptogenesis
1.3 Classification of Post-Arrest Seizure Activity
| Category | Description | Detection Method | Prognostic Significance |
|---|---|---|---|
| Convulsive seizures | Clinically apparent tonic-clonic, tonic, or clonic movements | Direct observation | Depends on EEG background and response to treatment |
| Non-convulsive seizures (NCS) | Electrographic seizure activity without clinically apparent motor manifestations | cEEG only | Common in paralyzed and deeply sedated patients; detection requires cEEG |
| Non-convulsive status epilepticus (NCSE) | Continuous or recurrent electrographic seizures for ≥30 minutes without return to baseline (or discrete seizures for >50% of any 1-hour recording) | cEEG only | Associated with poor outcome; may be partially treatable |
| Convulsive status epilepticus (CSE) | Continuous or recurrent convulsive seizures for ≥5 minutes without recovery between episodes | Clinical observation ± EEG | Requires immediate aggressive treatment |
| Myoclonic status epilepticus | Continuous generalized myoclonus with EEG correlate (epileptiform discharges time-locked to myoclonic jerks) | Clinical + EEG | Strongly associated with poor outcome when occurring early (<48 hours) on a suppressed or burst-suppression background |
| Cortical myoclonus (without status) | Intermittent myoclonic jerks with or without EEG correlate | Clinical ± EEG | Prognostic significance depends on EEG background |
| Subcortical myoclonus | Rhythmic or arrhythmic jerks without cortical EEG correlate | Clinical + EEG (no cortical correlate) | Not epileptic in nature; does not require antiepileptic treatment |
2. Continuous EEG Monitoring
2.1 Indications
Continuous EEG (cEEG) monitoring is recommended for all comatose post-cardiac arrest patients. The primary indications are:1 2 3
| Indication | Details |
|---|---|
| Seizure detection | Detection of non-convulsive seizures and NCSE, which are clinically silent and require cEEG for diagnosis |
| Seizure treatment monitoring | Assessment of treatment response; determination of whether seizures have resolved or transformed to purely electrographic activity |
| Prognostication | Assessment of EEG background activity, reactivity, and evolution for neuroprognostic purposes (see Part 3) |
| Monitoring during neuromuscular blockade | Mandatory if NMB agents are used (e.g., for shivering during TTM), as all clinical seizure manifestations are abolished by paralysis |
| Monitoring during sedation | Detection of breakthrough seizures in sedated patients |
2.2 Duration of Monitoring
| Clinical Scenario | Recommended Duration |
|---|---|
| Comatose post-arrest, no seizures detected | Minimum 24 hours; consider 48 hours if EEG background is not clearly benign or highly malignant |
| Seizures detected and treated | Continue cEEG for ≥24 hours after last seizure or after treatment escalation |
| During neuromuscular blockade | Entire duration of NMB + at least 12–24 hours after NMB is discontinued |
| Ongoing diagnostic uncertainty | Continue as clinically needed; extend monitoring if background is evolving or intermediate patterns are present |
2.3 Practical Considerations
- Electrode application: Standard 21-electrode 10-20 system is ideal; reduced montage (8–10 electrodes) is acceptable for rapid initiation when full montage setup would cause delay
- Quantitative EEG (qEEG) trending: Color density spectral array (CDSA) and amplitude-integrated EEG (aEEG) displays assist nursing and non-neurologist clinicians in detecting changes between neurotelemetry reviews
- Artifact management: ICU environment produces significant artifact (60 Hz electrical interference, ventilator motion, nursing care activities); experienced EEG technologists and neurophysiologists are essential for reliable interpretation
- Real-time review: In institutions with neurotelemetry capability, real-time or near-real-time (within 1 hour) review is preferred; at minimum, formal review should occur every 12 hours
3. Seizure Treatment Protocol
3.1 General Principles
| Principle | Details |
|---|---|
| Treat clinical seizures aggressively | Ongoing seizures increase cerebral metabolic demand, exacerbate secondary brain injury, and may worsen outcome |
| Electrographic seizures on cEEG | Treatment is recommended, though the evidence that treating purely electrographic seizures improves outcomes is limited; the decision to treat should consider the EEG background (seizures on a reactive background are more likely to respond and may have prognostic significance) |
| Myoclonic status epilepticus on a suppressed/burst-suppression EEG | Treatment is unlikely to improve neurologic outcome; aggressive antiepileptic escalation is generally not recommended in this context; focus on comfort and prognostication |
| Do not use seizure treatment as the sole reason to continue or withdraw life-sustaining treatment | Seizure activity informs prognosis but is only one component of multimodal assessment |
3.2 Stepwise Treatment Protocol for Post-Arrest Seizures and Status Epilepticus
The following protocol follows a stepwise escalation approach consistent with the standard tiered treatment of status epilepticus, adapted for the post-cardiac arrest context:1 3 4
Tier 1 — Emergent Initial Therapy (First 5–10 minutes)
| Agent | Dose | Route | Notes |
|---|---|---|---|
| Lorazepam | 0.1 mg/kg IV (max 4 mg per dose; may repeat once) | IV | First-line benzodiazepine; rapid onset; longer duration than midazolam |
| Midazolam | 0.2 mg/kg IM (max 10 mg) or 0.1 mg/kg IV (max 4 mg) | IM or IV | Preferred if IV access is not available; IM route is effective |
| Diazepam | 0.15 mg/kg IV (max 10 mg; may repeat once) | IV | Alternative to lorazepam |
Key point: Most comatose post-arrest patients in the ICU will already have IV access and may be receiving continuous sedation. Benzodiazepine boluses are appropriate as first-line treatment for acute seizures even in sedated patients.
Tier 2 — Urgent Control Therapy (Second-Line AEDs, 10–30 minutes)
If seizures persist despite initial benzodiazepine treatment, initiate one of the following:
| Agent | Loading Dose | Maintenance Dose | Advantages | Disadvantages |
|---|---|---|---|---|
| Levetiracetam | 40–60 mg/kg IV (max 4500 mg) infused over 15 minutes | 500–1500 mg IV every 12 hours | No significant drug interactions; no hepatic metabolism; no significant hemodynamic effects; no sedation | Limited evidence for efficacy in status epilepticus specifically; may be less effective than valproate for convulsive SE |
| Valproic acid / sodium valproate | 30–40 mg/kg IV (max 3000 mg) infused over 10 minutes | 10–15 mg/kg/day IV divided every 8–12 hours | Broad-spectrum efficacy; effective in multiple seizure types; evidence for efficacy in CSE | Hepatotoxicity risk; pancreatitis; thrombocytopenia; hyperammonemia; teratogenic (avoid in women of childbearing age); drug interactions |
| Lacosamide | 200–400 mg IV over 15 minutes | 100–200 mg IV every 12 hours | Minimal drug interactions; well-tolerated hemodynamically; no hepatic metabolite concern | Sodium channel blocker — use with caution in patients with cardiac conduction disease (PR prolongation); limited evidence as first-line for SE |
| Phenytoin / fosphenytoin | Phenytoin 20 mg/kg IV at max rate 50 mg/min; Fosphenytoin 20 mg PE/kg IV at max rate 150 mg PE/min | 5–7 mg/kg/day divided; target level 10–20 μg/mL | Long track record; effective | Cardiac toxicity (arrhythmias, hypotension during infusion); purple glove syndrome; nonlinear kinetics; drug interactions; fosphenytoin preferred over phenytoin if available |
Agent selection considerations in post-arrest patients:
- Levetiracetam is often preferred first due to its favorable drug interaction and hemodynamic profile
- Valproic acid may be preferred if seizures are refractory to levetiracetam or if a broad-spectrum agent is needed
- Lacosamide is an alternative with good tolerability but should be used cautiously in patients with cardiac conduction abnormalities (common post-arrest)
- Phenytoin/fosphenytoin remains effective but carries more risk in the hemodynamically unstable post-arrest patient
Tier 3 — Refractory Status Epilepticus (Continuous Infusion Therapy)
If seizures persist despite Tier 1 + Tier 2 therapy (refractory status epilepticus), initiate continuous infusion of an anesthetic agent:4
| Agent | Loading Dose | Infusion Range | EEG Target | Notes |
|---|---|---|---|---|
| Midazolam | 0.2 mg/kg IV bolus | 0.05–2.0 mg/kg/h | Seizure suppression or burst-suppression (if intractable) | Tachyphylaxis common; accumulates in renal failure |
| Propofol | 1–2 mg/kg IV bolus | 1–5 mg/kg/h (≤80 μg/kg/min) | Seizure suppression or burst-suppression | Rapid onset; risk of propofol infusion syndrome (PRIS) at high doses or prolonged use (>48 hours at >5 mg/kg/h); monitor triglycerides, CK, lactate |
| Pentobarbital | 5 mg/kg IV at 25–50 mg/min | 0.5–5 mg/kg/h | Burst-suppression with 5–10 second inter-burst intervals | Most potent anticonvulsant; profound hemodynamic depression; immunosuppression; prolonged half-life; typically reserved for super-refractory SE |
| Ketamine | 1.5–3 mg/kg IV bolus | 1–5 mg/kg/h | Seizure suppression | NMDA receptor antagonist; may be neuroprotective; less hemodynamic depression; increasingly used as an adjunct or alternative; limited evidence in post-arrest SE specifically |
Principles for Tier 3 management:
- cEEG monitoring is mandatory during continuous infusion therapy
- Titrate infusion to achieve the EEG goal (seizure cessression or burst-suppression, as determined by the clinical context)
- Maintain suppressive therapy for 24–48 hours before attempting a slow taper
- Taper gradually (reduce by 25–50% every 6–12 hours) while monitoring cEEG for seizure recurrence
- Continue maintenance AEDs (Tier 2 agents) throughout Tier 3 treatment and taper
3.3 Myoclonus — Specific Management Considerations
| Clinical Scenario | Management Approach |
|---|---|
| Early status myoclonus (<48 hours) on suppressed/burst-suppression EEG | Associated with extremely poor prognosis. Aggressive antiepileptic escalation is unlikely to improve neurologic outcome. Provide comfort measures. Focus on multimodal neuroprognostication (see Part 3). Do not use refractory myoclonus as sole basis for WLST — complete multimodal assessment first. |
| Myoclonus with epileptiform EEG correlate on reactive background | May represent a treatable condition. Trial of antiepileptic therapy is reasonable (levetiracetam, valproic acid, or clonazepam). Monitor response on cEEG. |
| Subcortical myoclonus (no EEG correlate) | Not epileptic. Antiepileptic drugs are ineffective. If distressing to the patient (if any awareness) or family, consider clonazepam 0.5–2 mg IV/PO BID-TID or valproic acid for symptomatic relief. |
| Lance-Adams syndrome (action myoclonus during recovery) | Indicates cortical recovery. Does NOT indicate poor prognosis. Treat symptomatically with levetiracetam (first-line), valproic acid, clonazepam, or piracetam. May require long-term management. Consider neurology consultation for optimization. |
3.4 Antiepileptic Drug Dosing Reference Table
| Agent | Loading Dose | Maintenance | Target Level | Key Monitoring |
|---|---|---|---|---|
| Levetiracetam | 40–60 mg/kg IV (max 4500 mg) | 500–1500 mg IV/PO Q12H | Not routinely monitored; 12–46 μg/mL if desired | Behavioral changes; thrombocytopenia (rare) |
| Valproic acid | 30–40 mg/kg IV (max 3000 mg) | 10–15 mg/kg/day IV/PO divided Q8–12H | 50–100 μg/mL (total); free level if low albumin | LFTs; ammonia; platelets; lipase |
| Lacosamide | 200–400 mg IV | 100–200 mg IV/PO Q12H | 10–20 μg/mL if monitored | ECG (PR interval); dizziness |
| Phenytoin / Fosphenytoin | 20 mg/kg (or PE/kg) IV | 5–7 mg/kg/day; adjust by level | 10–20 μg/mL (total); 1–2 μg/mL (free) | Free level in hypoalbuminemia, renal failure; cardiac monitoring during load; drug interactions |
| Clonazepam | 0.5–1 mg IV | 0.5–2 mg PO/IV BID-TID | Not routinely monitored | Sedation; respiratory depression |
| Phenobarbital | 15–20 mg/kg IV at ≤60 mg/min | 1–3 mg/kg/day | 15–40 μg/mL | Sedation; respiratory depression; hemodynamic effects; induces hepatic enzymes |
4. Organ Donation
4.1 Overview
Patients who die after cardiac arrest represent a significant proportion of deceased organ donors. Organ donation should be considered as a natural extension of end-of-life care in patients with confirmed poor neurologic prognosis. The intersection of neuroprognostication and organ donation requires careful coordination to ensure both ethical prognostication and maximal opportunity for donation.1 5
4.2 Identification of Potential Donors
| Pathway | Description | Timing |
|---|---|---|
| Donation after brain death (DBD) | Patient progresses to brain death (complete and irreversible cessation of all brain function, including brainstem); formal brain death determination per institutional and legal requirements | After neuroprognostication confirms irreversible injury; brain death testing per protocol |
| Donation after circulatory death (DCD) | Withdrawal of life-sustaining treatment in a patient with poor but not brain-dead prognosis; death declared after circulatory arrest | After multimodal neuroprognostication and family/patient goals-of-care decision to withdraw LST |
4.3 Key Principles
| Principle | Details |
|---|---|
| Decouple prognostication from donation | The team providing neuroprognostication and recommending goals-of-care should be separate from the organ procurement organization and transplant team. Families must not perceive that the prognosis is being influenced by organ procurement interests. |
| Do not hasten prognostication for donation purposes | The multimodal prognostication timeline (≥72 hours) must be respected regardless of organ donation potential. Premature WLST for the purpose of facilitating donation is ethically unacceptable. |
| Early notification of OPO | The organ procurement organization (OPO) should be notified early when a patient is identified as unlikely to survive, per legal requirements in most jurisdictions. This notification does not imply a commitment to donation and allows the OPO to coordinate if donation proceeds. |
| Family-centered approach | Organ donation should be discussed as an option, not an expectation. Trained requestors (either OPO staff or hospital-based) should discuss donation. The decision to donate is the family’s (or patient’s, if advance directive exists). |
| Support organ viability | If the family consents to donation, maintain hemodynamic and ventilatory support to preserve organ function. Standard donor management protocols apply. |
4.4 Brain Death Determination — Brief Overview
While a comprehensive brain death protocol is beyond the scope of this guideline, the key requirements include:6
| Requirement | Details |
|---|---|
| Prerequisites | Established etiology sufficient to cause brain death; absence of confounders (hypothermia, drug intoxication, severe metabolic derangement, neuromuscular blockade) |
| Core temperature | ≥36°C (before and during testing) |
| Clinical examination | Absence of all brainstem reflexes: pupils (fixed and dilated), corneal, oculocephalic, oculovestibular (cold calorics), cough/gag, motor response to noxious stimuli |
| Apnea test | Absence of respiratory effort with PaCO2 ≥60 mmHg (and ≥20 mmHg above baseline) for an adequate observation period (typically 8–10 minutes) |
| Number of examinations | Most institutional protocols and state laws require two examinations separated by a defined observation period (typically 6–24 hours); single examination acceptable in some jurisdictions with confirmatory testing |
| Confirmatory testing (if needed) | Cerebral angiography (absence of intracranial blood flow), EEG (electrocerebral silence), nuclear medicine brain perfusion scan, or transcranial Doppler |
4.5 DCD Considerations in Post-Arrest Patients
- DCD (Maastricht Category III — controlled DCD) is applicable when the family and care team decide to withdraw life-sustaining treatment based on a determined poor prognosis
- The patient must not meet brain death criteria (otherwise, DBD is the appropriate pathway)
- After WLST, death is declared based on circulatory criteria (typically 5 minutes of asystole or absent pulse/BP)
- Organ recovery proceeds immediately after death declaration
- Warm ischemia time (from WLST to organ preservation) is the critical determinant of graft function
- Kidneys, liver, lungs, and pancreas can be successfully transplanted via DCD; cardiac DCD (donation after circulatory death — heart transplantation) is an emerging practice
5. Post-ICU Care and Long-Term Recovery
5.1 Overview of Recovery Trajectory
Neurologic recovery after cardiac arrest follows a variable and often prolonged trajectory. While some patients demonstrate rapid recovery of consciousness (within hours to days), others experience a protracted recovery course spanning weeks to months. A substantial proportion of survivors — including those who ultimately achieve functional independence — experience persistent cognitive, psychological, and physical impairments that require structured rehabilitation and support.1 7 8
5.2 Cognitive Impairment After Cardiac Arrest
| Domain | Prevalence in Survivors | Characteristics |
|---|---|---|
| Memory (particularly short-term and new learning) | 30–50% | Most common cognitive deficit; hippocampal vulnerability; may be permanent |
| Executive function | 25–40% | Impaired planning, decision-making, mental flexibility; frontal lobe sensitivity to hypoxia |
| Attention and processing speed | 20–40% | Difficulty with sustained attention and multitasking |
| Visuospatial function | 15–25% | Impaired spatial reasoning and navigation |
| Language | 5–15% | Less commonly affected than other domains |
5.3 Psychological Sequelae
| Condition | Prevalence | Features | Screening Tool |
|---|---|---|---|
| Anxiety | 30–50% | Generalized anxiety, panic attacks, health anxiety, fear of recurrence | GAD-7 |
| Depression | 25–40% | Persistent low mood, anhedonia, fatigue, sleep disturbance | PHQ-9 |
| Post-traumatic stress disorder (PTSD) | 20–30% | Intrusive memories (may relate to resuscitation or ICU experience), hypervigilance, avoidance behaviors | PCL-5 (PTSD Checklist) |
| Fatigue | 50–70% | Persistent, disproportionate fatigue that limits function; not fully explained by physical deconditioning | Fatigue Severity Scale |
| Reduced quality of life | 40–60% | Composite effect of cognitive, psychological, and physical impairments | EQ-5D, SF-36 |
5.4 Cardiac Rehabilitation
Cardiac rehabilitation is recommended for cardiac arrest survivors, particularly those with an underlying cardiac etiology. The goals include physical reconditioning, secondary cardiovascular prevention, psychological support, and return to functional independence.9
| Phase | Timing | Components |
|---|---|---|
| Phase I (Inpatient) | During hospitalization | Early mobilization; education; medication optimization; psychosocial support; assessment for rehabilitation needs |
| Phase II (Outpatient — supervised) | 2–12 weeks after discharge | Structured exercise program (typically 36 sessions); dietary counseling; smoking cessation; medication review; psychological screening; return-to-work planning |
| Phase III (Maintenance) | Ongoing | Community-based exercise; lifestyle modification; ongoing secondary prevention; periodic reassessment |
5.5 Implantable Cardioverter-Defibrillator (ICD) Evaluation
ICD implantation is a critical component of secondary prevention for survivors of cardiac arrest due to ventricular arrhythmia (VF/pVT).1 10
| Clinical Scenario | ICD Recommendation | Notes |
|---|---|---|
| Cardiac arrest due to VF/pVT without a completely reversible cause | ICD recommended (Class I) | Standard secondary prevention indication; reduces mortality |
| Cardiac arrest due to VF/pVT with a completely reversible cause (e.g., acute STEMI with successful revascularization, severe electrolyte abnormality that has been corrected, drug toxicity) | ICD not routinely recommended; reassess after reversible cause corrected | Reversibility must be confirmed; repeat risk stratification (LVEF, EP study) at 40 days to 3 months |
| Non-ischemic cardiomyopathy with LVEF ≤35% | ICD recommended per primary prevention guidelines | Follow standard heart failure ICD criteria |
| Post-arrest LVEF ≤35% due to acute MI | Reassess LVEF at 40 days to 3 months after revascularization before ICD decision | Post-arrest myocardial stunning may transiently reduce LVEF; many patients recover LVEF beyond the ICD threshold |
| Hypertrophic cardiomyopathy, Brugada syndrome, long QT syndrome, ARVC, or other channelopathies | ICD evaluation per disease-specific guidelines | Genetic counseling and family screening |
Timing of ICD evaluation:
- ICD decision should typically be made before hospital discharge in patients with a clear indication (cardiac arrest without reversible cause)
- In patients with potentially reversible causes or post-MI stunning, defer ICD decision 40 days to 3 months for reassessment of LVEF and arrhythmia risk
- A wearable cardioverter-defibrillator (WCD / LifeVest) may be prescribed as a bridge to ICD implantation or to protect high-risk patients during the evaluation period
5.6 Cognitive Rehabilitation
| Intervention | Description | Evidence |
|---|---|---|
| Neuropsychological assessment | Formal cognitive testing to identify specific deficits and guide rehabilitation | Recommended for all survivors with subjective or observed cognitive impairment; typically at 3–6 months post-arrest |
| Cognitive rehabilitation therapy | Structured programs addressing memory, attention, executive function through compensatory strategies and restorative exercises | Moderate evidence for benefit in acquired brain injury; limited cardiac arrest-specific data; extrapolated from TBI and stroke rehabilitation literature |
| Occupational therapy | Functional adaptation strategies; return-to-work planning; adaptive equipment | Recommended for survivors with functional limitations |
| Speech and language therapy | Address communication deficits; cognitive-linguistic therapy | When indicated by neuropsychological assessment |
5.7 Psychological Support
| Intervention | Description | When to Initiate |
|---|---|---|
| Screening for anxiety, depression, PTSD | Use validated screening tools (GAD-7, PHQ-9, PCL-5) at hospital discharge, 3 months, and 12 months | At hospital discharge and at each follow-up |
| Cognitive behavioral therapy (CBT) | First-line psychological intervention for anxiety, depression, and PTSD in cardiac arrest survivors | When screening indicates significant symptoms |
| Peer support programs | Survivor-led support groups; shared experience | At any point during recovery; many patients find peer support uniquely valuable |
| Family/caregiver support | Assessment and support for family members and caregivers, who experience high rates of anxiety, depression, PTSD, and caregiver burden | From the ICU stay onward; ongoing |
5.8 Structured Follow-Up Pathway
| Time Point | Assessment Components |
|---|---|
| Hospital discharge | Medication reconciliation; cardiac device (ICD/WCD) plan; rehabilitation referral; driving restriction counseling; safety assessment; family education; psychological screening |
| 2–4 weeks post-discharge | Cardiology follow-up; device check (if applicable); medication review; symptom assessment; early identification of complications |
| 3 months | Cardiac rehabilitation progress; LVEF reassessment (if ICD decision pending); neuropsychological screening; psychological screening (GAD-7, PHQ-9, PCL-5); return-to-work assessment |
| 6 months | Comprehensive outcome assessment (CPC, mRS); cognitive assessment; quality-of-life assessment; cardiac device interrogation; ongoing rehabilitation needs |
| 12 months | Long-term outcome assessment; review secondary prevention targets; reassess cognitive and psychological function; ongoing rehabilitation planning |
6. Quality Metrics and Performance Improvement
6.1 Recommended Quality Metrics for Post-Cardiac Arrest Care
Systematic tracking of quality metrics enables institutional benchmarking, identification of care gaps, and continuous performance improvement. The following metrics are recommended based on the major resuscitation and critical care consensus statements:1 2 11
| Metric | Target | Rationale |
|---|---|---|
| Time from ROSC to target temperature | < 4 hours (if hypothermia is the chosen strategy); < 1 hour for initiation of temperature monitoring and fever prevention | Measures efficiency of TTM initiation; early temperature management is associated with better outcomes |
| Fever burden (temperature > 37.7°C) in first 72 hours | Minimize total time and degree of fever exposure | Fever is independently associated with worse neurologic outcome; active fever prevention is the minimum standard |
| Time from ROSC to coronary angiography (in STEMI patients) | Standard STEMI door-to-balloon targets (< 90 minutes from PCI-capable hospital arrival) | Acute coronary reperfusion is time-sensitive |
| Coronary angiography rate in STEMI patients | > 90% (unless contraindicated or death before catheterization) | Ensures all eligible STEMI patients receive emergent angiography |
| Continuous EEG monitoring initiation | Within 24 hours of ROSC in comatose patients | Seizure detection; prognostication |
| Neuroprognostication timing | ≥72 hours after ROSC (or normothermia if TTM used); documented multimodal assessment | Prevents premature WLST; ensures adequate evaluation |
| Multimodal neuroprognostication | ≥2 concordant modalities documented before determination of poor prognosis | Reduces risk of self-fulfilling prophecy |
| Survival to hospital discharge | Track and benchmark against national registries | Overall care quality indicator |
| Neurologic outcome at discharge and 6 months | CPC 1–2 or mRS 0–3 (favorable outcome) | Primary patient-centered outcome |
| Organ donation referral rate | 100% of eligible deaths referred to OPO | Legal requirement in most jurisdictions; maximizes donation opportunity |
6.2 The Cardiac Arrest Registry to Enhance Survival (CARES) and Other Registries
| Registry | Coverage | Purpose | Website |
|---|---|---|---|
| CARES | US national registry for OHCA | Standardized data collection; benchmarking; quality improvement | https://mycares.net |
| Get With The Guidelines — Resuscitation | US hospital-based registry for IHCA | In-hospital cardiac arrest outcomes; process measures; benchmarking | https://www.heart.org/en/professional/quality-improvement/get-with-the-guidelines |
| EuReCa | European Registry of Cardiac Arrest | Pan-European OHCA outcomes; cross-national comparisons | https://www.eureca-one.eu |
| ILCOR STAR | International | Systematic collection of resuscitation science data | https://ilcor.org |
6.3 Utstein Style Reporting
The Utstein style is the internationally standardized template for reporting cardiac arrest data and outcomes. Key data elements include:12
| Category | Key Data Elements |
|---|---|
| System | EMS response time, dispatcher-assisted CPR, first responder defibrillation availability |
| Patient | Age, sex, comorbidities, arrest location (home, public, healthcare facility) |
| Arrest | Witnessed vs. unwitnessed; bystander CPR; first monitored rhythm (VF/pVT, PEA, asystole); etiology (presumed cardiac vs. non-cardiac) |
| Process | Time to first defibrillation; time to ROSC; time to hospital arrival; time to TTM initiation; coronary angiography (yes/no, timing); neuroprognostication (timing, modalities used) |
| Outcome | ROSC (yes/no); survival to hospital admission; survival to hospital discharge; neurologic outcome at discharge (CPC, mRS); 30-day and 6-month survival and neurologic outcome |
7. Driving Restrictions After Cardiac Arrest
Driving restrictions are an important but often overlooked aspect of post-arrest care. Regulations vary by jurisdiction, but general guidance is consistent across most professional societies:10
| Scenario | Recommended Restriction | Notes |
|---|---|---|
| Cardiac arrest survivor with ICD implanted | Minimum 6-month driving restriction for private vehicles; permanent restriction for commercial driving (CDL) in most jurisdictions | Varies by country/state; some jurisdictions require 3 months for private vehicles |
| Cardiac arrest survivor without ICD (fully reversible cause) | Minimum 3–6 month restriction depending on etiology and treatment | Individualized assessment based on recurrence risk |
| WCD (wearable defibrillator) | Driving restricted while wearing WCD | WCD shock may cause temporary incapacity |
| Any survivor with cognitive impairment | Individual assessment; formal driving evaluation may be required | Occupational therapy driving assessment if cognitive deficits identified |
8. Ethical Considerations in Post-Cardiac Arrest Care
8.1 Goals-of-Care Discussions
| Principle | Details |
|---|---|
| Initiate early, update frequently | Begin goals-of-care discussions with families early in the ICU course; provide honest, compassionate updates; avoid premature prognostication but do not withhold information |
| Shared decision-making | Integrate the medical team’s assessment with the patient’s known values, advance directives, and family input |
| Cultural sensitivity | Recognize cultural, religious, and personal differences in attitudes toward life-sustaining treatment, brain death, and organ donation |
| Avoid anchoring bias | Do not allow the initial impression (e.g., prolonged arrest, non-shockable rhythm) to prematurely fix the prognosis; complete multimodal assessment before final determination |
| Document thoroughly | Record all neuroprognostication findings, the multimodal assessment, family discussions, and the rationale for goals-of-care decisions |
8.2 Withdrawal of Life-Sustaining Treatment (WLST)
| Consideration | Details |
|---|---|
| Timing | WLST should not occur before multimodal neuroprognostication is complete (≥72 hours after ROSC/normothermia) unless brain death has been declared or there is a medical reason unrelated to neurologic prognosis (e.g., refractory multiorgan failure) |
| Process | Should involve the attending physician, the neurology team (if consulted), nursing, and other relevant team members; family conference to explain findings and support decision-making |
| Comfort care | If WLST is decided, ensure comprehensive comfort care (symptom management, dignity, family presence, spiritual support) |
| Organ donation | Should be discussed as an option (not an obligation) with families when WLST is planned, per institutional and legal requirements |
References
Panchal AR, Bartos JA, Cabanas JG, et al. “Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Circulation. 2020;142(16_suppl_2):S366-S468. DOI: 10.1161/CIR.0000000000000916 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Nolan JP, Sandroni C, Bottiger BW, et al. “European Resuscitation Council and European Society of Intensive Care Medicine Guidelines 2021: Post-resuscitation Care.” Resuscitation. 2021;161:220-269. DOI: 10.1016/j.resuscitation.2021.02.012 ↩︎ ↩︎ ↩︎
Ruijter BJ, Tjepkema-Cloostermans MC, Tromp SC, et al. “Early electroencephalography for outcome prediction of postanoxic coma: A prospective cohort study.” Ann Neurol. 2019;86(2):203-214. DOI: 10.1002/ana.25518 ↩︎ ↩︎ ↩︎
Brophy GM, Bell R, Claassen J, et al. “Guidelines for the Evaluation and Management of Status Epilepticus.” Neurocrit Care. 2012;17(1):3-23. DOI: 10.1007/s12028-012-9695-z ↩︎ ↩︎
Dalle-Ave A, Shaw D, Bhatt DL. “Neuroprognostication and organ donation after cardiac arrest.” Resuscitation. 2022;176:12-17. DOI: 10.1016/j.resuscitation.2022.05.007 ↩︎
Greer DM, Shemie SD, Lewis A, et al. “Determination of Brain Death/Death by Neurologic Criteria: The World Brain Death Project.” JAMA. 2020;324(11):1078-1097. DOI: 10.1001/jama.2020.11586 ↩︎
Moulaert VR, Verbunt JA, van Heugten CM, et al. “Cognitive impairments in survivors of out-of-hospital cardiac arrest: a systematic review.” Resuscitation. 2009;80(3):297-305. DOI: 10.1016/j.resuscitation.2008.10.034 ↩︎
Lilja G, Nielsen N, Friberg H, et al. “Cognitive Function in Survivors of Out-of-Hospital Cardiac Arrest After Target Temperature Management at 33°C Versus 36°C.” Circulation. 2015;131(15):1340-1349. DOI: 10.1161/CIRCULATIONAHA.114.014414 ↩︎
Anderson L, Oldridge N, Thompson DR, et al. “Exercise-Based Cardiac Rehabilitation for Coronary Heart Disease: Cochrane Systematic Review and Meta-Analysis.” J Am Coll Cardiol. 2016;67(1):1-12. DOI: 10.1016/j.jacc.2015.10.044 ↩︎
Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. “2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.” J Am Coll Cardiol. 2018;72(14):e91-e220. DOI: 10.1016/j.jacc.2017.10.054 ↩︎ ↩︎
Kronick SL, Kurz MC, Lin S, et al. “Part 4: Systems of Care and Continuous Quality Improvement: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.” Circulation. 2015;132(18_suppl_2):S397-S413. DOI: 10.1161/CIR.0000000000000258 ↩︎
Perkins GD, Jacobs IG, Nadkarni VM, et al. “Cardiac Arrest and Cardiopulmonary Resuscitation Outcome Reports: Update of the Utstein Resuscitation Registry Templates for Out-of-Hospital Cardiac Arrest.” Circulation. 2015;132(13):1286-1300. DOI: 10.1161/CIR.0000000000000144 ↩︎